Dalbavancin is a novel lipoglycopeptide with activity against S. aureus, including glycopeptide 9 resistant isolates. The in vivo investigation reported here tested the impact of infection higher 10
The current studies were designed to define the pharmacodynamics target for dalbavancin 29 against S. aureus strains with dalbavancin MICs at or above the current FDA breakpoint (>0.12 30 μg/mL) and some of which were vancomycin intermediate (VISA) (24) (25) (26) (27) (28) (29) . The results from 31 these studies provide a pharmacodynamic rationale in support of the current clinical dosing 32 regimens. Furthermore, the data provide a starting point for the development of revised 33 susceptibility breakpoints for this new compound. were studied ( Table 1) . The MIC values of dalbavancin and vancomycin were determined in 37 triplicate using CLSI reference broth microdilution methodology in the presence P80 (30). The 38 dalbavancin MIC range for the S. aureus isolates was 0.12 to 0.50 µg/mL-. Animals were 39 maintained in accordance with the criteria of the American Association for Accreditation of 40 Laboratory Animal Care. All animal studies were approved by the Animal Research Committee 41 of the William S. Middleton Memorial VA Hospital. The neutropenic murine thigh infection 42 model was used for all studies. Mice were inoculated with 10 7 CFU/ml of each strain. Single-43 dose plasma pharmacokinetic studies were performed with thigh-infected mice given 44 intraperitoneal doses (0.2 ml/dose) of dalbavancin (2.5, 10, 40, 80 and 160 mg/kg). Dalbavancin 45 plasma concentrations were measured by an LC/MS/MS assay (Figure 1) . The lower limit of 46 quantification for the assay was 0.05 µg/ml. Sample analysis QC precision (%CV) ranged from 47 5% to 6.4% and accuracy (%bias) ranged from -3.5% to -10.0%. Peak levels were observed by 48 2-6 h. Dalbavancin exhibited relatively linear pharmacokinetics based upon the dose-AUC 49 relationship. The half-life was prolonged and varied from 4.1-9.31 h. A protein binding value of 50 98.4% was utilized based upon prior studies in this model (31) . 51
52
The in vivo virulence of the S. aureus isolates was similar in the untreated control mice based 53 upon the increase in thigh burden over the treatment period, 2.30 ± 0.14 log 10 CFU/thigh. Two 54 hours after infection, dalbavancin was administered via the intraperitoneal route with one of 55 seven two-fold-escalating intraperitoneal doses of dalbavancin every 12 h (2.5, 5, 10, 20, 40, 56 80, and 160 mg/kg) for a six day treatment period. Untreated control groups were sampled at 57 the start of therapy and end of study. The thighs were removed from each animal and 58 immediately processed for CFU determination. The results of these studies were analyzed by 59 using the sigmoid dose-effect model (32). The magnitude of the PK/PD index associated with 60 each endpoint dose was calculated from the following equation: log10 D = log 10 [E/(Emax -61 E)]/(N +log 10 ED 50 ), where E is the control growth for the static dose (D), E is the control growth 62 -1 log unit for a D of 1-log killing, and E is the control -2 log units for a D of 2-log killing. 63
64
A 1-log and 2-log kill was achieved against 7 and 6 of the isolates, respectively (Figure 1A and 65 Table 2 ). The dalbavancin in vivo exposure response data was also considered relative to the 66 PK/PD linked driver, AUC/MIC, using free drug concentrations. Drug accumulation was 67 calculated and included in AUC estimates. Using a sigmoid Emax model the data fit was strong 68 for the seven strain dataset (R 2 0.86) as shown in Figure 2B . The numeric AUC/MIC values 69 associated with each of the three treatment endpoints are also shown in were associated with 1-and 2-log reductions in organism burdens in the neutropenic mice, 72 respectively. 73
74
These PK/PD targets are lower than those observed previously with wild-type S. aureus strains 75 in this same model(31). This is in part due to lower pharmacokinetic values measured in the 76 present study, perhaps due to differences in the drug assay method. Of note, the present 77 kinetic study included a robust sampling scheme and a more sensitive and accurate drug assay 78 method compared to the prior animal model investigation. Specifically, we used specific LC-79 MS//MS assay compared to the prior bioassay. The treatment studies were otherwise similar 80 with regard to animal species, neutropenia, antibiotic (dalbavancin), drug preparation, route of 81 administration, treatment duration, study endpoints, and data analysis. 82
83
The present studies were designed to discern the PK/PD impact of infection with less common, 84 S. aureus that had dalbavancin MICs at or above the current dalbavancin FDA breakpoint 85 (<0.12 µg/mL). Dalbavancin demonstrated potent in vivo activity against S. aureus strains with 86 higher MICs, including those exhibiting a VISA phenotype. While it will be important to 87 corroborate these preclinical findings with data from patients, consideration of the AUC/MIC 88 target from these studies in the context of human pharmacokinetics would suggest a safe 89 treatment margin against these higher MIC isolates. If one considers the steady state kinetics 90 of dalbavancin in patients relative to the stasis, 1 and 2 log AUC/MIC targets in this study, the 91 MIC breakpoints would be revised to 4, 2, and 1 µg/ml, respectively .  92   93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120  121  122  123  Table 1 burden of organisms was measured at the start and end of therapy. The horizontal line at 0 145
represents the burden of organisms in the thighs of mice at the start of therapy. Data points 146 below the line represent killing and points above the line represent growth. The R 2 represents 147
the coefficient of determination. The ED 50 represents the AUC/MIC associated with 50% of the 148 maximal effect (E max ), and N is the slope of the relationship or the Hill coefficient. The line drawn 149
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